NCT06216301 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06216301
Title	LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)
Acronym	LUNAR-2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	NovoCure GmbH
Indications	lung non-squamous non-small cell carcinoma lung non-small cell carcinoma
Therapies	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NLD \| ITA \| ISR \| HUN \| FRA \| ESP \| DEU \| CZE \| CHE \| BEL \| AUT

NCT06216301
Clinical Trial Detail